Literature DB >> 14506698

Pattern of secondary genomic changes in pancreatic tumors of Tgf alpha/Trp53+/- transgenic mice.

Bettina Schreiner1, Dorothee M Baur, Alexander A Fingerle, Ulrich Zechner, Florian R Greten, Guido Adler, Bence Sipos, Günter Klöppel, Horst Hameister, Roland M Schmid.   

Abstract

Trp53(+/-) mice overexpressing Tgfalpha in a pancreas-specific manner represent a well-established animal model for pancreatic cancer. In this study we analyzed 38 pancreatic adenocarcinomas of these mice for secondary genomic changes by comparative genomic hybridization (CGH), loss of heterozygosity (LOH) analysis, real-time PCR, and methylation-specific analysis. CGH screening of the tumors revealed a recurrent pattern of genomic changes. In more than 50% of the tumors, chromosome 11 was affected. The gain of the proximal part spans about 16 cM, including the genes for Egfr, Rel, and Stk10. The distal part of chromosome 11, which contains the Trp53 locus, was deleted. LOH analysis proved that almost all tumors segregate the wild-type Trp53 allele. The Cdkn2a locus on chromosome 4 was inactivated by hypermethylation in 55% of all tumors. In addition, two other changes were detected in a mutually exclusive manner: overrepresentation of part of chromosome 15, or more rarely, loss of the distal part of chromosome 14. Together these data suggest the induction of a uniform pattern of secondary genomic changes in this transgenic tumor model for pancreatic cancer. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506698     DOI: 10.1002/gcc.10285

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Insights into the role of DNA methylation in disease through the use of mouse models.

Authors:  Melissa Conerly; William M Grady
Journal:  Dis Model Mech       Date:  2010 May-Jun       Impact factor: 5.758

2.  High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Authors:  Meredith C Henderson; Irma M Gonzales; Shilpi Arora; Ashish Choudhary; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses; David O Azorsa
Journal:  Mol Cancer Res       Date:  2011-05-02       Impact factor: 5.852

3.  Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.

Authors:  Scott C Borinstein; Melissa Conerly; Slavomir Dzieciatkowski; Swati Biswas; M Kay Washington; Patty Trobridge; Steve Henikoff; William M Grady
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

Review 4.  Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis.

Authors:  Wanglong Qiu; Gloria H Su
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

Review 5.  Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models.

Authors:  Brian T DeCant; Daniel R Principe; Carmen Guerra; Marina Pasca di Magliano; Paul J Grippo
Journal:  Front Physiol       Date:  2014-12-04       Impact factor: 4.566

6.  Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability.

Authors:  Jeran K Stratford; Feng Yan; Rebecca A Hill; Michael B Major; Lee M Graves; Channing J Der; Jen Jen Yeh
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.